Exelixis Inc. logo

Exelixis Inc. (EX9)

Market Open
23 Jun, 20:00
38. 09
+3.43
+9.9%
- Market Cap
80.72 P/E Ratio
0% Div Yield
0 Volume
0.61 Eps
34.66
Previous Close
Day Range
36 38.73
Year Range
19.84 42.9
Want to track EX9 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 49 days

Summary

EX9 trading today higher at €38.09, an increase of 9.9% from yesterday's close, completing a monthly increase of 2.34% or €0.87. Over the past 12 months, EX9 stock gained 20.04%.
EX9 is not paying dividends to its shareholders.
The last earnings report, released on Apr 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.04%, based on the last three reports. The next scheduled earnings report is due on Aug 12, 2025.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

EX9 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.

Seekingalpha | 14 hours ago
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from.

Businesswire | 1 day ago
Here's Why Exelixis (EXEL) is a Strong Value Stock

Here's Why Exelixis (EXEL) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 5 days ago

Exelixis Inc. Dividends

EX9 is not paying dividends to its shareholders.

Exelixis Inc. Earnings

12 Aug 2025 (In 1 month) Date
0.47
Cons. EPS
-
EPS
28 Apr 2025 Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
0.49
Cons. EPS
0.55
EPS
29 Oct 2024 Date
0.35
Cons. EPS
0.4
EPS
28 Oct 2024 Date
-
Cons. EPS
-
EPS
EX9 is not paying dividends to its shareholders.
12 Aug 2025 (In 1 month) Date
0.47
Cons. EPS
-
EPS
28 Apr 2025 Date
-
Cons. EPS
-
EPS
4 Feb 2025 Date
0.49
Cons. EPS
0.55
EPS
29 Oct 2024 Date
0.35
Cons. EPS
0.4
EPS
28 Oct 2024 Date
-
Cons. EPS
-
EPS

Exelixis Inc. (EX9) FAQ

What is the stock price today?

The current price is €38.09.

On which exchange is it traded?

Exelixis Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is EX9.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.47.

When is the next earnings date?

The next earnings report will release on Aug 12, 2025.

Has Exelixis Inc. ever had a stock split?

No, there has never been a stock split.

Exelixis Inc. Profile

Biotechnology Industry
Healthcare Sector
Dr. Michael M. Morrissey Ph.D. CEO
XDUS Exchange
US30161Q1040 ISIN
US Country
1,147 Employees
- Last Dividend
- Last Split
7 Apr 2000 IPO Date

Overview

Exelixis, Inc. is an oncology-focused biopharmaceutical company dedicated to the development and commercialization of new medicines for the treatment of difficult-to-treat cancers. With its headquarters in Alameda, California, the company has been advancing cancer care since its inception in 1994, initially operating under the name Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Exelixis has a robust portfolio of products available in the United States, alongside a dynamic pipeline of investigational drugs in development, reflecting its commitment to improving outcomes for patients facing complex cancer challenges. The company has established a substantial network of research collaborations and license agreements with leading pharmaceutical and biotechnology companies, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company, among others. This extensive collaboration network supports the company's strategic approach to drug development and enhances its ability to bring innovative cancer treatments to market.

Products and Services

  • CABOMETYX: This tablet formulation is designed for the treatment of patients with advanced renal cell carcinoma who have previously received anti-angiogenic therapy. CABOMETYX operates as an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors, highlighting its multifaceted approach to targeting cancer growth.
  • COMETRIQ: Available as capsules, COMETRIQ targets progressive and metastatic medullary thyroid cancer. Like CABOMETYX, COMETRIQ is derived from cabozantinib and inhibits several tyrosine kinases critical to cancer proliferation.
  • COTELLIC: This product is an inhibitor of MEK and is used in a combination regimen to treat certain forms of advanced melanoma. It showcases Exelixis's commitment to developing combination therapies that target various pathways involved in cancer growth.
  • MINNEBRO: An oral non-steroidal selective blocker of the mineralocorticoid receptor, MINNEBRO is approved for the treatment of hypertension in Japan. It represents Exelixis's efforts in addressing conditions that may accompany or result from cancer treatment.
  • Zanzalintinib: Currently in development, zanzalintinib is a potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors and the TAM kinases (TYRO3, AXL, and MER). This investigational drug reflects Exelixis's ongoing research into novel cancer treatments.
  • XB002: Also under development, XB002 is a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC) administered via intravenous infusion. It consists of a human monoclonal antibody against TF conjugated to an auristatin-based microtubulin inhibitor payload, marking a cutting-edge approach to cancer therapy.

Contact Information

Address: 1851 Harbor Bay Parkway
Phone: 650 837 7000